VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (6643)	5/7/1999 5:26:00 PM
From: biowa	Read Replies (1) of 9719

Peter, All I heard was GI industry talk that Janssen was less than impressed. From other sources I guess I would question whether efficacy will be demonstrably better in the broad population, and the key question is will it avoid Propulsid®'s potential cardiac effects (which earned it the dread "black box"). By the way, it would be hard not to have a broader indication than cisapride which is for nocturnal regurgitation I believe (sorry, I'm not near my PDR). Of course cisapride is used so much off-label that the breadth of label is not a factor, IMO. Don't take me wrong, I like SEPR, just passing that along on one candidate in their pipeline. biowa

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next